一塩基多型（SNP）ジェノタイピング市場- 世界の産業規模、シェア、動向、機会、予測、セグメント、技術別、用途別、地域別、競合、2020年～2030年

一塩基多型（SNP）ジェノタイピングの世界市場規模は2024年に112億6,000万米ドルとなり、2030年までのCAGRは17.15%で、予測期間中に目覚ましい成長が見込まれています。

一塩基多型（SNP）ジェノタイピングは、SNPジェノタイピングと略されることが多く、個人のDNA内の一塩基多型（SNP）を同定・分析するために使用される分子生物学的手法です。SNPはヒトゲノムおよび他の多くの生物種のゲノムにおいて最も一般的な遺伝的変異です。SNPは、ゲノムの特定の位置で1つのヌクレオチド（A、T、C、G）が別のヌクレオチドに置換されるなど、DNA配列における1塩基対の変化を伴う。SNPジェノタイピングは、遺伝学やゲノミクス研究、臨床診断、その他様々な応用において重要なツールです。SNPジェノタイピングは、対象となる特定のSNPを同定することから始まる。これらのSNPは、形質、疾患、薬物応答、あるいはその他の遺伝的変異に関連することがあります。これらのSNPは通常、潜在的な生物学的あるいは臨床的関連性に基づいて選択されます。SNPジェノタイピングを実施するには、個体または生物からのDNAサンプルが必要です。これは、血液、唾液、頬ぬぐい液、組織サンプルなど、様々なソースから得ることができます。DNAは通常、サンプルから精製・抽出されます。

ファーマコゲノミクスの分野では、薬剤の選択と投与量を最適化するために、多くの場合SNPジェノタイピングによって得られる遺伝子データを利用します。これは、治療指数が狭い薬剤では特に重要です。SNPジェノタイピングは医薬品開発に不可欠です。薬剤ターゲットを特定し、臨床試験において患者集団を層別化し、医薬品の安全性と有効性を確保する上で役立ちます。SNPジェノタイピングは法医学的分析において、個人を特定し、関係を確立するために使用されます。家系検査会社は、SNPを用いて遺伝的遺産に関する洞察を提供しています。ハイスループット・ジェノタイピングや次世代シーケンシングなど、ジェノタイピング技術の継続的な進歩により、SNPジェノタイピングはより効率的で、費用対効果が高く、利用しやすいものとなっています。遺伝子データの共有や共同研究の取り組みがゲノミクスの発見を加速し、SNPジェノタイピングの需要をさらに促進しています。

主な市場促進要因

技術の進歩

法医学および家系検査における需要の増加

医薬品開発の増加

主な市場課題

コストとアクセシビリティ

遺伝子変異の複雑さ

主な市場動向

農業とバイオテクノロジー

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の一塩基多型（SNP）ジェノタイピング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別（TaqMan SNPジェノタイピング、Massarray SNPジェノタイピング、SNP GeneChipアレイ、その他）
  • 用途別（動物遺伝学、植物改良、診断研究、医薬品および薬理ゲノム学、農業バイオテクノロジー、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の一塩基多型（SNP）ジェノタイピング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の一塩基多型（SNP）ジェノタイピング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の一塩基多型（SNP）ジェノタイピング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の一塩基多型（SNP）ジェノタイピング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの一塩基多型（SNP）ジェノタイピング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の一塩基多型（SNP）ジェノタイピング市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• Douglas Scientific LLC
• Illumina Inc.
• Life Technologies Corp.
• Luminex Corp.
• Promega Corporation
• Thermo Fischer Scientific Inc.
• Fluidigm Corporation

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Single Nucleotide Polymorphism Genotyping Market was valued at USD 11.26 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 17.15% through 2030. Single Nucleotide Polymorphism Genotyping, often abbreviated as SNP Genotyping, is a molecular biology technique used to identify and analyze single nucleotide polymorphisms (SNPs) within an individual's DNA. SNPs are the most common type of genetic variation in the human genome and in the genomes of many other species. They involve a single base pair change in the DNA sequence, such as a substitution of one nucleotide (A, T, C, or G) for another at a specific position in the genome. SNP genotyping is a critical tool in genetics and genomics research, clinical diagnostics, and various other applications. SNP genotyping begins with the identification of specific SNPs of interest. These SNPs can be associated with traits, diseases, drug responses, or other genetic variations. They are typically selected based on their potential biological or clinical relevance. To perform SNP genotyping, a DNA sample from an individual or organism is required. This can be obtained from various sources, such as blood, saliva, buccal swabs, or tissue samples. The DNA is typically purified and extracted from the sample.

The field of pharmacogenomics uses genetic data, often obtained through SNP genotyping, to optimize drug selection and dosages. This is especially important for medications with a narrow therapeutic index. SNP genotyping is essential in drug development. It aids in identifying drug targets, stratifying patient populations in clinical trials, and ensuring the safety and efficacy of pharmaceutical products. SNP genotyping is used in forensic analysis to identify individuals and establish relationships. Ancestry testing companies use SNPs to provide insights into one's genetic heritage. Ongoing advancements in genotyping technologies, such as high-throughput genotyping and next-generation sequencing, have made SNP genotyping more efficient, cost-effective, and accessible. The sharing of genetic data and collaborative research efforts have accelerated discoveries in genomics, further fueling the demand for SNP genotyping.

Key Market Drivers

Technological Advancements

Next-Generation Sequencing (NGS) technologies, such as Illumina's sequencing platforms, have revolutionized genotyping. NGS allows for the simultaneous genotyping of thousands to millions of SNPs in a single experiment, making it a powerful tool for genome-wide association studies (GWAS) and other applications. DNA microarrays are used to simultaneously genotype thousands of SNPs. They offer a high-throughput and cost-effective approach to genotyping. Microarray-based platforms like Affymetrix and Illumina have gained widespread adoption. Real-time PCR-based assays, like TaqMan and allele-specific PCR, are used for SNP genotyping. These assays offer high specificity, sensitivity, and real-time data acquisition, making them valuable in research and clinical settings.

Digital PCR technology enables absolute quantification of target DNA molecules, including SNP alleles. It is highly precise and can detect rare alleles or variants with high accuracy. Mass spectrometry-based genotyping methods, such as MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization-Time of Flight), are used to analyze SNP alleles. These methods offer high throughput and accuracy. Allele-Specific Oligonucleotide Ligation Assay (ASO-LA) techniques involve hybridizing SNP-specific oligonucleotides with target DNA, followed by ligation of SNP-specific probes. This method is highly specific and can be used in multiplex format. Automation and robotics have enabled high-throughput SNP genotyping. These platforms, like Fluidigm's Biomark and Bio-Rad's BioMark HD, are suitable for large-scale genotyping projects. The use of nanotechnology, such as nanowires and nanoparticles, has been explored to improve the sensitivity and specificity of SNP genotyping assays. The CRISPR-Cas system can be adapted for SNP genotyping by designing guide RNAs that specifically target SNP sites. It allows for precise and multiplexed genotyping.

Advances in data analysis and bioinformatics tools have become crucial. Software for SNP calling, haplotype phasing, and interpretation of genotyping data has improved. The integration of SNP genotyping with single-cell analysis has allowed researchers to explore genetic diversity at the individual cell level, providing insights into clonal evolution and tissue heterogeneity. Efforts are ongoing to develop portable and point-of-care genotyping devices that can rapidly analyze SNP data at the bedside or in resource-limited settings. Advances in sample preparation techniques have reduced the time and cost associated with DNA extraction and purification, making genotyping more efficient. This factor will help in the development of the Global Single Nucleotide Polymorphism Genotyping Market.

Increase Demand in Forensic Science and Ancestry Testing

SNP genotyping is used in forensic DNA analysis to identify individuals, such as in criminal investigations. SNPs are highly polymorphic and can help distinguish one individual from another, even within a close biological relationship. SNPs can be used to analyze evidence collected from crime scenes, such as blood, hair, or other bodily fluids, to determine the genetic profile of a suspect or victim. SNP genotyping technology has been instrumental in solving cold cases by reexamining evidence from unsolved crimes, sometimes years or decades later. In cases where biological relationships need to be confirmed (e.g., paternity, or maternity testing), SNP genotyping can be used to establish family connections with a high degree of accuracy. In forensic anthropology and archaeology, SNP genotyping is used to identify human remains, especially in mass disasters or historical investigations. The molecular properties of Single Nucleotide Polymorphisms (SNPs) make them highly advantageous for forensic applications compared to Short Tandem Repeats (STRs). A key distinction lies in their mutation rates-SNPs demonstrate an exceptionally low mutation rate of approximately 1 in 100 million per replication, significantly lower than the mutation rate of STRs, which is around 1 in 1,000. This inherent stability enhances the reliability of SNPs for forensic analysis, particularly in applications requiring high precision, such as identity verification and genetic profiling.

Ancestry testing services, like 23andMe and Ancestry.com, utilize SNP genotyping to provide customers with information about their genetic heritage, including ancestral origins, migration patterns, and family tree connections. Consumers are interested in learning more about their heritage and ethnic background. SNP genotyping helps individuals trace their genetic roots and discover their ancestral origins. Ancestry testing relies on large reference databases of SNP data to compare an individual's genetic markers to global populations, allowing for estimates of the person's ancestry. Some ancestry testing services also offer insights into genetic health risks and inherited traits. SNP data is used to provide these personalized genetic reports. This factor will pace up the demand of the Global Single Nucleotide Polymorphism Genotyping Market

Rise in Drug Development

Identifying appropriate drug targets is a fundamental step in drug development. Single Nucleotide Polymorphism (SNP) genotyping is used to discover genetic variations associated with specific diseases, making it easier to identify potential drug targets. Understanding the genetic basis of a disease allows researchers to develop drugs that target the underlying causes. Drug development often involves clinical trials to test the safety and efficacy of new medications. Single Nucleotide Polymorphism genotyping helps stratify patient populations based on their genetic profiles, ensuring that the right patients are enrolled in clinical trials. This can increase the chances of success and lead to more personalized treatment approaches. Single Nucleotide Polymorphism genotyping is essential for pharmacogenomic studies, which examine how an individual's genetic makeup influences their response to drugs. This knowledge is critical for tailoring drug treatments to individual patients, optimizing dosages, and minimizing adverse reactions. Single Nucleotide Polymorphism genotyping can help predict how certain individuals might react to a drug, including whether they are at risk for adverse events. This information is invaluable in assessing a drug's safety profile. Single Nucleotide Polymorphism genotyping can be used to determine whether certain genetic variants in patients affect the drug's efficacy. This information can guide dosing adjustments and the selection of alternative treatments for non-responders. North America, predominantly the United States, holds a dominant share, contributing to more than 50% of global drug patent inventorship. European countries represent approximately one-third of inventors, while Asian nations account for just over 7% of the total. This distribution highlights the concentrated leadership of North America in pharmaceutical innovation, while also illustrating the growing involvement of European and Asian markets in global drug development.

Single Nucleotide Polymorphism genotyping is used to discover and validate biomarkers related to drug responses and treatment outcomes. These biomarkers can help streamline drug development and improve the accuracy of clinical trial results. Single Nucleotide Polymorphism genotyping is applied in animal models and preclinical studies to better understand how genetic factors influence drug metabolism, toxicity, and efficacy. In some cases, SNP genotyping is used to develop companion diagnostics that are paired with specific drugs to identify patients who are most likely to benefit from those treatments. This precision medicine approach is increasingly important in drug development. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), increasingly require pharmacogenomic data, including Single Nucleotide Polymorphism genotyping information, in drug submissions. This ensures that genetic factors are considered in drug development and safety assessments. By incorporating Single Nucleotide Polymorphism genotyping data, clinical trial designs can be optimized to maximize the chances of successful drug development, reduce costs, and accelerate the path to market. This factor will accelerate the demand of the Global Single Nucleotide Polymorphism Genotyping Market

Key Market Challenges

Cost and Accessibility

Many SNP genotyping technologies, such as next-generation sequencing (NGS) and microarrays, involve substantial costs for equipment, reagents, and data analysis. This can be a barrier for research institutions, clinical laboratories, and smaller companies with limited budgets. Ongoing costs related to reagents, consumables, and maintenance can be a significant financial burden. The high cost per sample for some genotyping methods may limit their use, especially in large-scale projects. While the cost of genotyping instruments has come down, the complexity of data analysis and the need for high-performance computing infrastructure can still be expensive. Effective bioinformatics support is often required to derive meaningful insights from genotyping data. The genotyping market has seen increased competition, which has driven companies to offer more cost-effective solutions. However, this competition can lead to market saturation, making it challenging for companies to differentiate their products based on cost. In resource-constrained settings, such as low- and middle-income countries, the high cost of genotyping technologies can limit access to advanced genetic testing and research capabilities. Access to SNP genotyping services and technologies can be limited in rural or remote areas, where advanced laboratories and infrastructure may not be available.

Complexity of Genetic Variations

The human genome is highly diverse, with millions of SNPs and other genetic variants spread across the genome. Understanding how specific SNPs are associated with traits, diseases, or drug responses can be challenging due to this inherent genetic heterogeneity. Rare and novel SNPs, which are not well-represented in reference databases, can be particularly challenging to identify and interpret. These variants may have important clinical implications, but their rarity makes them less accessible for genotyping and research. SNPs in close physical proximity on a chromosome can exhibit linkage disequilibrium, meaning they are inherited together. Interpreting the functional impact of a single SNP may require considering its relationships with neighboring SNPs. Genetic interactions, where the effect of one SNP is dependent on the presence of another SNP, can add complexity to genetic studies. Detecting and characterizing such interactions requires large datasets and sophisticated analytical methods. While SNP genotyping primarily focuses on single-nucleotide changes, structural variations like Copy Number Variations (CNVs) can also influence genetic traits and disease susceptibility. These require specialized genotyping and analysis methods. Many complex traits, including common diseases, are influenced by multiple SNPs and genes, as well as environmental factors. Untangling the contribution of individual SNPs in such contexts is intricate. Understanding the functional significance of SNPs, such as their impact on gene expression or protein function, is an ongoing challenge. Variants in non-coding regions can have important regulatory roles.

Key Market Trends

Agriculture and Biotechnology

SNP genotyping is used to identify specific genetic markers associated with desirable traits in crops, such as disease resistance, yield, and nutritional content. Genomic selection techniques help breeders make informed decisions about which plants to select for further breeding. SNP markers are employed in marker-assisted breeding programs to accelerate the development of new crop varieties with improved characteristics. This approach reduces the time required to develop and release new, high-performing crop varieties. Identifying SNP markers associated with disease resistance allows breeders to develop crop varieties that are more resilient to pests and pathogens, reducing the need for chemical interventions. SNP genotyping is applied to improve the genetic traits of livestock, including meat and dairy animals. Breeders use SNP data to select animals with the desired traits, such as growth rate, milk production, and disease resistance. SNP genotyping can be used to preserve and conserve the genetic diversity of livestock breeds, especially those at risk of extinction. Identifying SNP markers associated with disease resistance in livestock can reduce the economic losses associated with disease outbreaks and decrease the use of antibiotics. Biotechnological research often relies on SNP genotyping to understand the role of specific genetic variations in cellular processes, gene expression, and protein function. SNP genotyping data is used to identify associations between genetic variations and specific phenotypes, contributing to a deeper understanding of complex traits.

Segmental Insights

Technology Insights

In 2024, the Global Single Nucleotide Polymorphism Genotyping Market largest share was held by TaqMan SNP Genotyping segment and is predicted to continue expanding over the coming years. TaqMan SNP genotyping is a well-established and widely recognized genotyping technology. It has a proven track record for its accuracy and reliability in SNP detection. Researchers and laboratories often choose familiar and trusted technologies like TaqMan for their genotyping needs. TaqMan assays are known for their high specificity and sensitivity in detecting single nucleotide polymorphisms. This accuracy is critical in various applications, including genetics research, clinical diagnostics, and pharmaceutical development. TaqMan SNP genotyping assays can be customized to target specific SNPs of interest. This flexibility is valuable for researchers and clinical laboratories that want to study and monitor genetic variations. TaqMan SNP genotyping is scalable, making it suitable for handling both small and large sample sizes. This versatility allows laboratories to adapt their genotyping efforts to different research or diagnostic needs. TaqMan assays are well-suited for automation, making them efficient for processing a high volume of samples. This automation capability is particularly important in clinical and research settings where large-scale genotyping is required. Many laboratories and institutions have already invested in TaqMan-based genotyping platforms and instruments. This existing infrastructure makes it convenient for them to continue using TaqMan technology, and they may be more inclined to expand their use of TaqMan assays for SNP genotyping.

Regional Insights

The North America region dominated the Global Single Nucleotide Polymorphism Genotyping Market in 2024. North America, particularly the United States and Canada, has a strong tradition of scientific research and innovation. Many renowned research institutions, universities, and biotechnology companies are based in this region. These institutions drive SNP genotyping research and technological advancements. North America has a substantial investment in healthcare and biotechnology. Government funding, private investment, and venture capital play significant roles in supporting research and development in genomics and genetics. The region has access to state-of-the-art genotyping technologies and equipment. Leading companies in the genotyping industry, such as Illumina, Thermo Fisher Scientific, and Affymetrix (acquired by Thermo Fisher), are headquartered or have a strong presence in North America. North America is home to a sizable biopharmaceutical industry. SNP genotyping is essential for drug development, pharmacogenomics, and clinical trials. This proximity to pharmaceutical companies drives demand for SNP genotyping services and technologies. Government initiatives and research projects related to genetics, genomics, and personalized medicine contribute to the growth of the SNP genotyping market. The National Institutes of Health (NIH) and various Canadian research agencies fund many genomics projects.

Key Market Players

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• Douglas Scientific LLC
• Illumina Inc.
• Life Technologies Corp.
• Luminex Corp
  • Promega Corporation
• Thermo Fischer Scientific Inc.
• Fluidigm Corporation

Report Scope:

In this report, the Global Single Nucleotide Polymorphism Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Single Nucleotide Polymorphism Genotyping Market, By Technology:

• TaqMan SNP Genotyping
• Massarray SNP Genotyping
• SNP GeneChip Arrays
• Others

Single Nucleotide Polymorphism Genotyping Market, By Application:

• Animal Genetics
• Plant Improvement
• Diagnostic Research
• Pharmaceuticals and Pharmacogenomics
• Agricultural Biotechnology
• Others

Single Nucleotide Polymorphism Genotyping Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Single Nucleotide Polymorphism Genotyping Market.

Available Customizations:

Global Single Nucleotide Polymorphism Genotyping Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five)

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Applications
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Single Nucleotide Polymorphism Genotyping Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (TaqMan SNP Genotyping, Massarray SNP Genotyping, SNP GeneChip Arrays, Others)
  • 5.2.2. By Application (Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Single Nucleotide Polymorphism Genotyping Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Single Nucleotide Polymorphism Genotyping Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
  • 6.3.2. India Single Nucleotide Polymorphism Genotyping Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
  • 6.3.3. Australia Single Nucleotide Polymorphism Genotyping Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
  • 6.3.4. Japan Single Nucleotide Polymorphism Genotyping Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Technology
      • 6.3.4.2.2. By Application
  • 6.3.5. South Korea Single Nucleotide Polymorphism Genotyping Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Technology
      • 6.3.5.2.2. By Application

7. Europe Single Nucleotide Polymorphism Genotyping Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Single Nucleotide Polymorphism Genotyping Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Single Nucleotide Polymorphism Genotyping Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
  • 7.3.3. Spain Single Nucleotide Polymorphism Genotyping Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Single Nucleotide Polymorphism Genotyping Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
  • 7.3.5. United Kingdom Single Nucleotide Polymorphism Genotyping Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application

8. North America Single Nucleotide Polymorphism Genotyping Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Single Nucleotide Polymorphism Genotyping Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
  • 8.3.2. Mexico Single Nucleotide Polymorphism Genotyping Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
  • 8.3.3. Canada Single Nucleotide Polymorphism Genotyping Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application

9. South America Single Nucleotide Polymorphism Genotyping Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Single Nucleotide Polymorphism Genotyping Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Single Nucleotide Polymorphism Genotyping Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Single Nucleotide Polymorphism Genotyping Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application

10. Middle East and Africa Single Nucleotide Polymorphism Genotyping Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Single Nucleotide Polymorphism Genotyping Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Single Nucleotide Polymorphism Genotyping Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Single Nucleotide Polymorphism Genotyping Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Single Nucleotide Polymorphism Genotyping Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Agilent Technologies Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
• 16.2. Bio-Rad Laboratories Inc.
• 16.3. Danaher Corporation
• 16.4. Douglas Scientific LLC
• 16.5. Illumina Inc.
• 16.6. Life Technologies Corp.
• 16.7. Luminex Corp.
• 16.8. Promega Corporation
• 16.9. Thermo Fischer Scientific Inc.
• 16.10. Fluidigm Corporation

17. Strategic Recommendations

18. About Us & Disclaimer